Sickle Cell Disease

Overview

Sickle cell disease (SCD) is a group of inherited blood disorders caused by changes in the gene for beta-globin, a component of hemoglobin—the protein that carries oxygen in red blood cells. The resulting hemoglobin S can make red cells rigid and crescent-shaped, causing anemia, painful vaso-occlusive crises (blockages of small blood vessels), acute chest syndrome, stroke, and progressive organ damage. SCD disproportionately affects people of African ancestry and also affects Hispanic Americans; the most severe form, sickle cell anemia, can shorten life expectancy by more than 20 years. FDA overview CDC Vital Signs

Standard care aims to prevent and manage complications rather than remove the underlying genetic cause. It includes hydroxyurea, infection prevention, pain management, screening for organ complications, and red-cell transfusions when indicated. A donor blood-and-bone-marrow transplant can be curative for selected people with a suitable donor, but carries risks including graft-versus-host disease, infertility, infection, and transplant failure. In the United States, two autologous gene therapies are now approved: Casgevy (exagamglogene autotemcel), whose FDA record lists a July 1, 2026 expansion to patients aged 2 years and older with recurrent vaso-occlusive crises, and Lyfgenia (lovotibeglogene autotemcel), approved for patients aged 12 years and older with a history of vaso-occlusive events. NHLBI treatment overview FDA orphan-product record for Casgevy FDA Lyfgenia information

Scope of Recent Research (2020–present)

Research since 2020 has transformed SCD from a disease with one limited donor-transplant cure into one with approved gene-based treatments and multiple clinical editing platforms. The central questions are now how to achieve durable production of protective hemoglobin, eliminate vaso-occlusive crises with acceptable long-term safety, avoid toxic conditioning chemotherapy, and make treatment affordable and available globally. The field is close to functional cures for some eligible patients, but not yet to a simple, broadly accessible cure for most people living with SCD. NHLBI Cure Sickle Cell Initiative Exa-cel phase 3 study

Major Breakthroughs and Emerging Therapies

Gene editing to reactivate fetal hemoglobin. Casgevy is made from a patient’s own blood-forming stem cells, edited outside the body with CRISPR-Cas9 at an enhancer controlling BCL11A. This increases fetal hemoglobin (HbF), the naturally protective hemoglobin normally prominent before birth, which reduces hemoglobin S polymerization and red-cell sickling. In a phase 3 study, 29 of 30 evaluable participants were free of severe vaso-occlusive crises for at least 12 consecutive months, while all 30 were free of vaso-occlusive-crisis hospitalizations for that period; the median follow-up among the 44 infused participants was 19.3 months. Exa-cel phase 3 study

Lentiviral gene addition. Lyfgenia uses a lentiviral vector to add a modified beta-globin gene to a patient’s own stem cells, enabling production of an anti-sickling hemoglobin called HbA^T87Q. In the pivotal phase 1–2 LentiGlobin study, all 25 evaluable participants with sufficient follow-up had resolution of severe vaso-occlusive events after infusion, compared with a median 3.5 severe events annually before enrollment. This approach does not directly repair the sickle mutation, but it supplies red cells with a functional, anti-sickling hemoglobin. LentiGlobin clinical study

Next-generation editing approaches. Reni-cel, developed by Editas Medicine, uses CRISPR-Cas12a to disrupt BCL11A binding sites in the promoters of the fetal-globin genes HBG1 and HBG2, rather than editing the BCL11A enhancer itself. In the phase 1–2 RUBY study, 27 of 28 treated participants had no vaso-occlusive events after infusion at the October 2024 data cutoff; among those with at least six months of data, mean HbF rose to 48.1% and mean total hemoglobin to 13.8 g/dL. The sponsor ended the study early for development-priority reasons, so these encouraging results require confirmation in a continued development program or equivalent studies. Reni-cel RUBY study RUBY trial registry

Base editing and direct correction. Beam Therapeutics’ risto-cel uses base editing, a form of gene editing designed to change individual DNA letters without creating the usual double-strand DNA break. In the interim phase 1–2 BEACON analysis, 31 participants received treatment; HbF exceeded 60% of total hemoglobin at six months among those with available data, and no investigator-reported severe vaso-occlusive crises occurred after the post-transfusion assessment window. In parallel, preclinical researchers are pursuing direct repair of the sickle mutation through prime editing and other precision-editing methods, seeking to restore normal adult hemoglobin rather than relying on HbF reactivation. Risto-cel BEACON study In vivo prime-editing study

Clinical Trials and Experimental Approaches

The completed or recently reported clinical evidence is strongest for autologous stem-cell products given after myeloablative busulfan conditioning chemotherapy. Vertex Pharmaceuticals and CRISPR Therapeutics sponsored the phase 3 CLIMB SCD-121 trial of exa-cel; bluebird bio sponsored the phase 1–2 HGB-206 LentiGlobin study that supported Lyfgenia; and Editas Medicine sponsored the phase 1–2 RUBY trial of reni-cel. These programs assess durable stem-cell engraftment, hemoglobin production, vaso-occlusive events, hospitalizations, and serious adverse events over prolonged follow-up. Exa-cel phase 3 study LentiGlobin clinical study Reni-cel RUBY study

The BEACON phase 1–2 trial of risto-cel, sponsored by Beam Therapeutics, is an important test of whether base editing can achieve high HbF with a different editing chemistry and target design. Its early results are promising but remain interim, with short and uneven follow-up and substantial treatment-related adverse-event monitoring still needed. BEACON trial registry Risto-cel BEACON study

Methodologies and Scientific Approaches

Most curative programs collect CD34-positive hematopoietic stem and progenitor cells from the patient, genetically modify them outside the body, and reinfuse them after chemotherapy clears marrow space for the corrected cells. Researchers measure engraftment, editing frequency, HbF and hemoglobin S fractions, total hemoglobin, markers of red-cell breakdown, vaso-occlusive events, hospitalizations, patient-reported quality of life, and possible off-target edits or secondary cancers. Exa-cel phase 3 study Risto-cel BEACON study

A major experimental goal is to eliminate stem-cell collection, intensive chemotherapy, and specialized transplant infrastructure. In mouse models of human sickle-cell disease, bone-marrow-homing lipid nanoparticles have delivered messenger RNA and CRISPR or base-editing components to marrow stem cells, producing edits intended either to reactivate fetal hemoglobin or convert sickle-associated sequences toward non-sickle forms. Such in vivo delivery remains preclinical, but it could eventually support less toxic and more scalable treatment. Bone-marrow-homing lipid nanoparticles In vivo prime-editing study

Leading Institutions and Funding

The National Heart, Lung, and Blood Institute leads the NIH Cure Sickle Cell Initiative, which coordinates academic, industry, clinical, and patient-community partners to advance safe and broadly adoptable genetic cures. Major clinical and scientific contributors include St. Jude Children’s Research Hospital, the National Institutes of Health, Boston Children’s Hospital, the University of California San Francisco, the Broad Institute-affiliated research community, and multinational transplant centers, alongside companies including Vertex Pharmaceuticals, CRISPR Therapeutics, bluebird bio, Editas Medicine, and Beam Therapeutics. NHLBI Cure Sickle Cell Initiative Exa-cel phase 3 study Risto-cel BEACON study

Public funding has supported both clinical translation and access-oriented innovation. In 2021, the California Institute for Regenerative Medicine committed $17.32 million across three clinical-trial-stage SCD projects, including $8.33 million for a Boston Children’s Hospital fetal-hemoglobin gene-transfer study and $8.39 million for a UCSF CRISPR-corrected stem-cell transplant study. CIRM Cure Sickle Cell awards

Strengths, Limitations, and Challenges

The central strength of current gene therapies is that a single treatment can produce long-lasting blood-cell production from the patient’s own modified stem cells, avoiding donor matching and graft-versus-host disease. Clinical results with gene addition, CRISPR-Cas9 editing, Cas12a editing, and base editing show large increases in protective hemoglobin and dramatic reductions in vaso-occlusive crises in selected participants. Exa-cel phase 3 study LentiGlobin clinical study Reni-cel RUBY study Risto-cel BEACON study

The principal limitations are the toxicity and burden of myeloablative conditioning, risks to fertility, the need for prolonged hospitalization and expert transplant care, uncertain lifelong durability, and the need to monitor for off-target editing or treatment-associated blood cancers. Access is also a profound challenge: individualized cell manufacturing and transplant delivery are expensive and difficult to provide in many regions where SCD is most prevalent. These realities make lower-toxicity conditioning, in vivo delivery, manufacturing simplification, and equitable financing as important as the editing technology itself. NHLBI treatment overview FDA approval announcement Bone-marrow-homing lipid nanoparticles

Outlook and Future Directions

As of August 8, 2026, SCD has entered an era in which functional cure is achievable for a growing subset of patients through donor transplant or autologous gene therapy, but the next milestone is a cure that is safer, simpler, less costly, and deployable worldwide. The most consequential developments to watch are long-term follow-up of approved products, confirmation of base-editing and Cas12a-editing results in larger cohorts, expansion to younger children, fertility-preserving or non-genotoxic conditioning, and successful in vivo stem-cell editing. FDA orphan-product record for Casgevy NHLBI Cure Sickle Cell Initiative Bone-marrow-homing lipid nanoparticles

References

• FDA approval announcement — U.S. Food and Drug Administration, 2023.
• FDA Lyfgenia information — U.S. Food and Drug Administration, 2023.
• FDA orphan-product record for Casgevy — U.S. Food and Drug Administration, 2026.
• CDC Vital Signs — Centers for Disease Control and Prevention, 2022.
• NHLBI treatment overview — National Heart, Lung, and Blood Institute, 2024.
• NHLBI Cure Sickle Cell Initiative — National Heart, Lung, and Blood Institute, 2026.
• Exa-cel phase 3 study — Frangoul et al., New England Journal of Medicine, 2024.
• LentiGlobin clinical study — Kanter et al., New England Journal of Medicine, 2022.
• Reni-cel RUBY study — Hanna et al., New England Journal of Medicine, 2026.
• RUBY trial registry — ClinicalTrials.gov, 2026.
• Risto-cel BEACON study — Gupta et al., New England Journal of Medicine, 2026.
• BEACON trial registry — ClinicalTrials.gov, 2026.
• In vivo prime-editing study — Li et al., Blood, 2023.
• Bone-marrow-homing lipid nanoparticles — Lian et al., Nature Nanotechnology, 2024.
• CIRM Cure Sickle Cell awards — California Institute for Regenerative Medicine, 2021.